



Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry

Karen M. Olsson^{1,2}, Marius M. Hoeper ^{1,2}, Christine Pausch³, Ekkehard Grünig⁴, Doerte Huscher⁵, David Pittrow ^{3,6}, Stephan Rosenkranz⁷ and Henning Gall ^{2,8}

¹Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany. ²German Centre of Lung Research (DZL), Germany. ³GWT-TUD GmbH, Epidemiological Centre, Dresden, Germany. ⁴Centre for Pulmonary Hypertension, Thoraxclinic Heidelberg GmbH at Heidelberg University Hospital, Heidelberg, Germany. ⁵Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin, Berlin, Germany. ⁶Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany. ⁷Clinic III for Internal Medicine (Cardiology) and Center for Molecular Medicine (CMMC), and the Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany. ⁸Dept of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany.

Marius M. Hoeper (hoeper.marius@mh-hannover.de)



Shareable abstract (@ERSpublications)

In patients with pulmonary hypertension associated with interstitial lung disease, pulmonary vascular resistance provides stronger prognostic information than mean pulmonary arterial pressure <https://bit.ly/3w1QcIS>

Cite this article as: Olsson KM, Hoeper MM, Pausch C, *et al.* Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. *Eur Respir J* 2021; 58: 2101483 [DOI: 10.1183/13993003.01483-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org

This article has an editorial commentary:
<https://doi.org/10.1183/13993003.02008-2021>

Received: 25 May 2021
Accepted: 17 June 2021

To the Editor:

Pulmonary hypertension (PH) is a common complication of many chronic lung diseases, especially COPD and interstitial lung disease (ILD) [1]. In these conditions, the development of PH is associated with an aggravation of symptoms and an increase in mortality risk. In most patients with chronic lung disease, the haemodynamic severity of PH is mild to moderate, while some patients develop severe PH, which is presently defined by a mean pulmonary arterial pressure (mPAP) ≥ 35 mmHg or mPAP ≥ 25 mmHg in the presence of a cardiac index $< 2.0 \text{ L} \cdot \text{min}^{-1} \cdot \text{m}^{-2}$ [2]. These haemodynamic criteria were introduced per expert consensus but were not based on solid data.

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org